EA201790543A1 - Способы лечения заболевания или расстройства с использованием составов для перорального применения, содержащих аналоги цитидина, в комбинации с моноклональным антителом к pd1 или pdl1 - Google Patents

Способы лечения заболевания или расстройства с использованием составов для перорального применения, содержащих аналоги цитидина, в комбинации с моноклональным антителом к pd1 или pdl1

Info

Publication number
EA201790543A1
EA201790543A1 EA201790543A EA201790543A EA201790543A1 EA 201790543 A1 EA201790543 A1 EA 201790543A1 EA 201790543 A EA201790543 A EA 201790543A EA 201790543 A EA201790543 A EA 201790543A EA 201790543 A1 EA201790543 A1 EA 201790543A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorders
pdl1
combination
treating diseases
compositions
Prior art date
Application number
EA201790543A
Other languages
English (en)
Russian (ru)
Inventor
Абдеррахим Фанди
Дэвид Рейсер
Дебора Бартон
Дамир Биджик
Original Assignee
Селджин Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селджин Корпорейшн filed Critical Селджин Корпорейшн
Publication of EA201790543A1 publication Critical patent/EA201790543A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201790543A 2014-09-08 2015-09-08 Способы лечения заболевания или расстройства с использованием составов для перорального применения, содержащих аналоги цитидина, в комбинации с моноклональным антителом к pd1 или pdl1 EA201790543A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462047463P 2014-09-08 2014-09-08
PCT/US2015/048812 WO2016040238A1 (en) 2014-09-08 2015-09-08 Methods for treating a disease or disorder using oral formulations of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody

Publications (1)

Publication Number Publication Date
EA201790543A1 true EA201790543A1 (ru) 2017-07-31

Family

ID=54150681

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790543A EA201790543A1 (ru) 2014-09-08 2015-09-08 Способы лечения заболевания или расстройства с использованием составов для перорального применения, содержащих аналоги цитидина, в комбинации с моноклональным антителом к pd1 или pdl1

Country Status (12)

Country Link
US (1) US20160067336A1 (enExample)
EP (1) EP3191104A1 (enExample)
JP (1) JP2017526700A (enExample)
KR (1) KR20170045237A (enExample)
CN (1) CN106604745A (enExample)
AU (1) AU2015315435A1 (enExample)
CA (1) CA2960490A1 (enExample)
EA (1) EA201790543A1 (enExample)
IL (1) IL250887A0 (enExample)
MX (1) MX2017002875A (enExample)
SG (1) SG11201701710SA (enExample)
WO (1) WO2016040238A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
MA42971A (fr) * 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
US11287428B2 (en) 2016-03-16 2022-03-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. PD1 and PDL-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia
CA3026563C (en) 2016-06-10 2023-11-28 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
WO2018007554A1 (en) * 2016-07-06 2018-01-11 Pierre Fabre Medicament Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination
BR112019006504A2 (pt) * 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
WO2018160717A1 (en) * 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
CN110913906A (zh) * 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
US12168054B2 (en) 2017-05-19 2024-12-17 Syndax Pharmaceuticals, Inc. Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
CA3069672A1 (en) 2017-07-13 2019-01-17 Io Therapeutics, Inc. Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
CA3073953A1 (en) 2017-08-31 2019-03-07 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
EP3880191A4 (en) * 2018-11-13 2022-08-10 Yee, Amy COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY
CN113543806A (zh) * 2019-03-04 2021-10-22 北卡罗莱纳州立大学 结合表观遗传调控和免疫检查点阻断的药物递送
WO2020257671A1 (en) 2019-06-20 2020-12-24 Celgene Corporation Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
KR20210097882A (ko) * 2020-01-30 2021-08-10 삼성바이오에피스 주식회사 안정한 항-pd-1 항체 약제학적 제제
EP4132490A4 (en) * 2020-04-07 2024-04-24 Metanoi Therapeutics, Inc. ETHANOLAMINE FORMULATION FOR THE TREATMENT OF EPITHELIAL OVARIAN CARCINOMA
MX2024004801A (es) 2021-10-19 2024-06-28 Akirabio Inc Composiciones que comprenden análogos de 2'- desoxicitidina, y uso de las mismas para el tratamiento de anemia de células falciformes, talasemia y cánceres.
KR20260057078A (ko) 2023-08-18 2026-04-27 브리스톨-마이어스 스큅 컴퍼니 Bcma 및 cd3에 결합하는 항체를 포함하는 조성물 및 치료 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036993A1 (es) * 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
WO2010036959A2 (en) * 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
EP2396007A1 (en) * 2009-02-10 2011-12-21 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
WO2013043569A1 (en) * 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US20140357567A1 (en) * 2011-11-01 2014-12-04 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
EP2958571B1 (en) * 2013-02-21 2024-04-10 Michele Maio Dna hypomethylating agents for cancer therapy
WO2015035112A1 (en) * 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation

Also Published As

Publication number Publication date
JP2017526700A (ja) 2017-09-14
SG11201701710SA (en) 2017-04-27
CN106604745A (zh) 2017-04-26
IL250887A0 (en) 2017-04-30
CA2960490A1 (en) 2016-03-17
WO2016040238A1 (en) 2016-03-17
AU2015315435A1 (en) 2017-03-23
KR20170045237A (ko) 2017-04-26
US20160067336A1 (en) 2016-03-10
EP3191104A1 (en) 2017-07-19
MX2017002875A (es) 2017-05-30

Similar Documents

Publication Publication Date Title
MX2017002875A (es) Metodos para tratar una enfermedad o trastorno usando formulaciones orales de analogos de citidina en combinacion con un anticuerpo monoclonal anti-pd1 o anti-pdl1.
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
EA201691361A1 (ru) Антитела к lag-3 для лечения гематологических злокачественных опухолей
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2023000889A (es) Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
EA202092609A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
CY1119042T1 (el) Υποκατεστημενες ξανθινες και μεθοδοι χρησης αυτων
PH12016501366A1 (en) Novel anti-baff antibodies
PH12020550908A1 (en) Anti-cxcr5 antibodies and compositions and uses thereof
MX2017000419A (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX392069B (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
SG10201901057UA (en) Anti-pd-l1 antibodies
MX2017001599A (es) Anticuerpos novedosos y sus usos.
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
PL422231A1 (pl) Komórki immunologiczne CAR do leczenia nowotworów
MX2020011993A (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
TR201900071T4 (tr) Kontrollü Over Stimülasyonuna Yönelik Bileşim
EA201690992A1 (ru) Антитела, специфичные к fcrn
EA201690388A1 (ru) Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов
MY194084A (en) Interferon beta antibodies and uses thereof